Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model

Journal of Pineal Research

Volumn 50, Issue 2, 2011, Pages 140-149

  Jung Hynes, Brittney ^a   Schmit, Travis L ^a   Reagan Shaw, Shannon R ^a   Siddiqui, Imtiaz A ^a   Mukhtar, Hasan ^a,b   Ahmad, Nihal ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

melatonin; prostate cancer; sirtuins; transgenic adenocarcinoma of mouse prostate

Indexed keywords

ENZYME INHIBITOR; KI 67 ANTIGEN; MELATONIN; MESSENGER RNA; SIRTUIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR MARKER;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE EFFECT; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOTHESIS; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMMUNOPRECIPITATION; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MELATONIN; MICE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79951632056     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2010.00823.x     Document Type: Article

References (40)

1. Jung-Hynes B, Nihal M, Zhong W, et al. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 2009; 284: 3823-3832.
2. Jung-Hynes B, Ahmad N,. Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle 2009; 8: 1478-1483.
3. Lara E, Mai A, Calvanese V, et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 2009; 28: 781-791.
4. Ota H, Tokunaga E, Chang K, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006; 25: 176-185. (Pubitemid 43083679)
5. Zhao W, Kruse JP, Tang Y, et al. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008; 451: 587-590. (Pubitemid 351186268)
6. Asher G, Gatfield D, Stratmann M, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell 2008; 134: 317-328. (Pubitemid 352024391)
7. Nakahata Y, Kaluzova M, Grimaldi B, et al. The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell 2008; 134: 329-340. (Pubitemid 352010336)
8. Lee C, Etchegaray JP, Cagampang FR, et al. Posttranslational mechanisms regulate the mammalian circadian clock. Cell 2001; 107: 855-867. (Pubitemid 34084977)
9. Torres-Farfan C, Seron-Ferre M, Dinet V, et al. Immunocytochemical demonstration of day/night changes of clock gene protein levels in the murine adrenal gland: differences between melatonin-proficient (C3H) and melatonin-deficient (C57BL) mice. J Pineal Res 2006; 40: 64-70.
10. Imbesi M, Arslan AD, Yildiz S, et al. The melatonin receptor MT1 is required for the differential regulatory actions of melatonin on neuronal clock gene expression in striatal neurons in vitro. J Pineal Res 2008; 46: 87-94.
11. Karasek M,. Does melatonin play a role in aging processes? J Physiol Pharmacol 2007; 58 (Suppl. 6): 105-113.
12. Jung B, Ahmad N,. Melatonin in cancer management: progress and promise. Cancer Res 2006; 66: 9789-9793. (Pubitemid 44672026)
13. Reagan-Shaw S, Nihal M, Ahsan H, et al. Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio. Prostate 2008; 68: 1624-1634.
14. Rasmussen DD, Boldt BM, Wilkinson CW, et al. Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology 1999; 140: 1009-1012. (Pubitemid 29058243)
15. Reagan-Shaw S, Nihal M, Ahmad N,. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661. (Pubitemid 351348146)
16. Zhigang Z, Jieming L, Su L, et al. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml. J Surg Oncol 2007; 96: 54-61. (Pubitemid 47015449)
17. Gupta S, Hastak K, Ahmad N, et al. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001; 98: 10350-10355. (Pubitemid 32803023)
18. Greenberg NM, Demayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439-3443.
19. Adhami VM, Siddiqui IA, Ahmad N, et al. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004; 64: 8715-8722. (Pubitemid 39552088)
20. Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004; 64: 3334-3343. (Pubitemid 38581441)
21. Raina K, Rajamanickam S, Singh RP, et al. Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice. Clin Cancer Res 2008; 14: 3177-3184.
22. Shi R, Berkel HJ, Yu H,. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001; 85: 991-996. (Pubitemid 33016002)
23. Longo VD, Kennedy BK,. Sirtuins in aging and age-related disease. Cell 2006; 126: 257-268. (Pubitemid 44092970)
24. Marmorstein R,. Structure and chemistry of the Sir2 family of NAD+-dependent histone/protein deactylases. Biochem Soc Trans 2004; 32: 904-909. (Pubitemid 39655500)
25. Hida Y, Kubo Y, Murao K, et al. Strong expression of a longevity-related protein, SIRT1, in Bowens disease. Arch Dermatol Res 2007; 299: 103-106. (Pubitemid 46669407)
26. Nakahata Y, Sahar S, Astarita G, et al. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science 2009; 324: 654-657.
27. Blask DE, Sauer LA, Dauchy RT,. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002; 2: 113-132.
28. Martin-Renedo J, Mauriz JL, Jorquera F, et al. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res 2008; 45: 532-540.
29. Tam CW, Chan KW, Liu VW, et al. Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance. J Pineal Res 2008; 45: 403-412.
30. Joo SS, Yoo YM,. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res 2009; 47: 8-14.
31. Dziegiel P, Podhorska-Okolow M, Zabel M,. Melatonin: adjuvant therapy of malignant tumors. Med Sci Monit 2008; 14: RA64-RA70. (Pubitemid 351679883)
32. Vivien-Roels B, Malan A, Rettori MC, et al. Daily variations in pineal melatonin concentrations in inbred and outbred mice. J Biol Rhythms 1998; 13: 403-409. (Pubitemid 128478937)
33. Chokkalingam AP, Pollak M, Fillmore CM, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001; 10: 421-427. (Pubitemid 32701626)
34. Platz EA, Pollak MN, Leitzmann MF, et al. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005; 16: 255-262. (Pubitemid 40897844)
35. Kaplan PJ, Mohan S, Cohen P, et al. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999; 59: 2203-2209. (Pubitemid 29217686)
36. Li H, Rajendran GK, Liu N, et al. SirT1 modulates the estrogen-insulin-like growth factor-1 signaling for postnatal development of mammary gland in mice. Breast Cancer Res 2007; 9: R1. doi
37. Dai Y, Ngo D, Forman LW, et al. Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol 2007; 21: 1807-1821. (Pubitemid 47173793)
38. Solomon JM, Pasupuleti R, Xu L, et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 2006; 26: 28-38.
39. Huffman DM, Grizzle WE, Bamman MM, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007; 67: 6612-6618. (Pubitemid 47105506)
40. Yang Y, Hou H, Haller EM, et al. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J 2005; 24: 1021-1032. (Pubitemid 40470150)